Gemcitabine for the Treatment of Patients with Osteosarcoma

Wei, Meiyang; Zhuang, Yanfeng; Wang, Wanming

doi:10.7314/apjcp.2014.15.17.7159

Cited by 10 publications

(7 citation statements)

References 28 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gemcitabine-induced antitumor therapy resistance is a widely used model in studying chemotherapeutic resistance ( 6 ). Gemcitabine is used as a standard drug treatment for human osteosarcoma and has a significant therapeutic effect in osteosarcoma ( 7 ), however, the underlying mechanism requires further investigation.…”

Section: Introductionmentioning

confidence: 99%

Wnt/β-catenin signaling pathway activation reverses gemcitabine resistance by attenuating Beclin1-mediated autophagy in the MG63 human osteosarcoma cell line

Hao

Chen

Liu

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

Anaberrant Wnt/β-catenin signaling pathway is frequently implicated in tumorigenesis. However, whether the Wnt/β-catenin pathway plays a role in resistance to antitumor chemotherapy drugs remains unknown. In the present study, the process of autophagy was assessed following overexpression of the autophagy-associated gene Beclin 1 in gemcitabine-induced MG63 human osteosarcoma cells. Autophagy-associated gene expression was measured following activation or inhibition of the Wnt/β-catenin pathway in gemcitabine-induced MG63 cells using reverse transcription-quantitative polymerase chain reaction. In addition, the percentage of MG63 cell apoptosis was measured by flow cytometry following Wnt/β-catenin pathway activation or inhibition. The results demonstrated that Beclin 1 overexpression induced autophagy and reduced gemcitabine-induced apoptosis in MG63 human cell line. Furthermore, activation of the Wnt/β-catenin signaling pathway attenuated autophagy and enhanced gemcitabine-induced apoptosis. Additionally, the expression of Beclin 1 was reduced following Wnt/β-catenin signaling pathway activation. The present study demonstrated that activation of the Wnt/β-catenin signaling pathway may rescue chemotherapy drug resistance by downregulating the expression of Beclin 1.

show abstract

Section: Introductionmentioning

confidence: 99%

Wnt/β-catenin signaling pathway activation reverses gemcitabine resistance by attenuating Beclin1-mediated autophagy in the MG63 human osteosarcoma cell line

Hao

Chen

Liu

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…Type I collagen can also induce chemo‐resistant gene expression or activate signaling cascades, which possess detoxification capability. Gemcitabine, a nucleoside analog, is widely used in the treatment of human cancers 93‐95 . In PDAC, elevated level of type I collagen enhances gemcitabine resistance by increasing the expression of high mobility group A2 (HMGA2), 96,97 a nonhistone DNA‐binding nuclear protein involved in chromatin remodeling and gene transcription 98 .…”

Section: Mechanisms Of Type I Collagen Regulating Tumor Progressionmentioning

confidence: 99%

Targeting type I collagen for cancer treatment

Shi

Zhang

Zhu

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

Collagen is the most abundant protein in animals. Interactions between tumor cells and collagen influence every step of tumor development. Type I collagen is the main fibrillar collagen in the extracellular matrix and is frequently upregulated during tumorigenesis. The binding of type I collagen to its receptors on tumor cells promotes tumor cell proliferation, epithelial-mesenchymal transition and metastasis. Type I collagen also regulates the efficacy of tumor therapies, such as chemotherapy, radiotherapy and immunotherapy. Furthermore, type I collagen fragments are diagnostic markers of metastatic tumors and have prognostic value. Inhibition of type I collagen synthesis has been reported to have antitumor effects in animal models. However, collagen has also been shown to possess antitumor activity. Therefore, the roles that type I collagen plays in tumor biology are complex and tumor type-dependent. In this review, we discuss the expression and regulation of synthesis of type I collagen, as well as the role upregulated type I collagen plays in various stages of cancer Abbreviations: *OH, hydroxyl radical; 5 0 UTR, 5 0 untranslated region; 5 0 SL, 5 0 stem-loop; ABC, ATP binding cassette; AKT, v-Akt murine thymoma viral oncogene homolog; BLCA, bladder urothelial

show abstract

“…Gemcitabine is another drug that has recently made its way into clinical trials for OS, and so far, has shown promising results [21], but its true impact remains to be appreciated. The reasons why there has been little advancement in the field primarily relate to the highly aggressive and genetically unstable nature of OS, as well as the highly toxic features of chemotherapy.…”

Section: Medical Treatmentmentioning

confidence: 99%

Pediatric Osteosarcoma: Connecting Present and Future Approaches to Diagnosis and Treatment

Kapetanos¹,

Asimakopoulos²,

Savvides

et al. 2020

BJSTR

View full text Add to dashboard Cite

Pediatric osteosarcoma is a highly aggressive type of cancer, affecting children of all ages. Early diagnosis is key to ensure better outcomes, as pre-metastatic lesions are easier to manage. For this reason, novel screening techniques, such as miRNA biomarkers, have been developed to complement the standard radiological approach to diagnosis. Furthermore, the standard of care in chemotherapeutic treatment is constantly revised, and new drugs are designed to minimize the toxic effects of the treatment whilst maintaining, or even improving, its efficacy. Immunotherapy and radiotherapy are two more disciplines which have demonstrated great promise in their capacity to exert strong anti-tumor properties in a clinical setting. Immunotherapeutic drugs like Mifamurtide, and radiological treatments such as proton beam therapy are starting to form an essential part of the golden standard of care. Lastly, innovations in orthopedic oncology provide surgical techniques with the potential to improve surgical outcomes whilst preserving as much of the patient's healthy tissue as possible. This review appreciates that there is a great promise held in the future of osteosarcoma treatment, and highlights where attention should be paid in the future.

show abstract

Gemcitabine for the Treatment of Patients with Osteosarcoma

Cited by 10 publications

References 28 publications

Wnt/β-catenin signaling pathway activation reverses gemcitabine resistance by attenuating Beclin1-mediated autophagy in the MG63 human osteosarcoma cell line

Wnt/β-catenin signaling pathway activation reverses gemcitabine resistance by attenuating Beclin1-mediated autophagy in the MG63 human osteosarcoma cell line

Targeting type I collagen for cancer treatment

Pediatric Osteosarcoma: Connecting Present and Future Approaches to Diagnosis and Treatment

Contact Info

Product

Resources

About